ClinicalTrials.gg
CompletedNCT05066724Updated Jun 13, 2025Results posted

Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

A Phase 2 interventional study of Centanafadine in Smoking Cessation, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.

Enrollment
648th of 872
50 · median 149
Started
2021
with 47 others
Phase 2
105 of 920
9 open now
Registered
743rd of 920
by date

Among the 920 studies in Smoking Cessation with a site in United States, this one is the 648th largest by enrollment of the 872 interventional ones that give a count, is one of 48 that started in 2021, is one of 105 in phase 2, and was the 743rd registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 920 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

This study will explore the efficacy and tolerability of centanafadine at a dose of 400 mg per day of centanafadine in promoting smoking abstinence in adult smokers seeking to quit.

Read the detailed description

This single-group, open-label study of 50 participants will explore the potential of centanafadine in promoting smoking abstinence in adult smokers seeking to quit. The efficacy and tolerability of centanafadine at a dose of 400 mg total daily dose (TDD) (200 mg twice a day (BID)) approximately 4 to 6 hours apart (during a 7-week treatment period) will be compared with a benchmark of abstinence based on historical data from clinical trials of varenicline, viewed as the most efficacious pharmacotherapy currently approved by the FDA.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the form (ICF) and is able to read and understand the information provided in the ICF.
  2. Smokers 21 to 65 years of age (inclusive) at screening.
  3. Smokes an average of at least 10 commercially available cigarettes per day for the last 12 months.
  4. Has an expired air carbon monoxide (CO) reading of at least 10 ppm at screening.
  5. At screening, express a desire to quit smoking within the next 30 days.
  6. (BMI) of 18 to 40 kg/m2, inclusive at screening.
  7. Willing and able to comply with the requirements of the study.
  8. Owns a smartphone with text message and data capabilities compatible with necessary surveys.

Exclusion criteria

Exclusion Criteria:

  1. Participants of (CBP) who are breastfeeding and/or have a positive pregnancy test result.
  2. Participant presenting with, or having a history of, uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure > 95 mmHg) or symptomatic hypotension.
  3. Participants with known ischemic heart disease or history of myocardial infarction, congestive heart failure (whether controlled or uncontrolled), angioplasty, stenting, coronary artery bypass surgery, or other serious cardiac problems that would place him/her at increased vulnerability to the sympathomimetic effects of stimulant medication.
  4. History of seizures (after the age of 17 years).
  5. Participants of CBP or sexually active participants unless they agree to practice 2 different methods of or remain abstinent during the course of the trial and for 30 days after the last dose of Investigation Medicinal Product (IMP) for participants of CBP, and 30 days after the last dose of IMP for participants with partners who are of CBP. Unless the participant is sterile (i.e., participants who have had a bilateral oophorectomy or hysterectomy or who have been for at least 12 consecutive months; or participants who have had a bilateral orchidectomy) or remains abstinent, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pills, birth control injection, birth control implant, birth control patch, condom with spermicide, or sponge with spermicide. Participants who do not agree to refrain from donating sperm from screening through 30 days after the last dose of IMP.
  6. Participant has a history of dermatologic adverse reactions secondary to any drug exposure or any active/uncontrolled dermatologic disease.
  7. Currently taking antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressants (TCAs), or monoamine oxidase inhibitors (MAOIs)), antipsychotics (such as butyrophenones, thioxanthenes, atypical antipsychotics or other heterocyclics), benzodiazepines, hypnotics, or medications that prolong Interval (QTc). MAOI's taken within 30 days of screening.
  8. Screening (Visit 1) or Baseline (Visit 2) Columbia-Suicide Severity Rating Scale (C-SSRS) score greater than 0 (any answer "Yes") for the SUICIDAL IDEATION section or greater than 0 for the SUICIDAL BEHAVIOR section (any answer "Yes").
  9. Substance use disorder within 12 months prior to screening.
  10. Participants that have a positive alcohol test (via breathalyzer or blood), a positive drug screen for illicit drugs (Table 6.3.5) at screening or baseline.

    Participants who test positive for marijuana at screening may be enrolled if they have no evidence of a substance use disorder and if they agree to refrain from use for the duration of the trial.

  11. Any participant who has any other medical or physical condition(s) that, in the opinion of the investigator, may prevent the participant from completing the trial or would go against the participant's best interest with participation in the trial. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol.
  12. Participants with abnormal laboratory tests, vital sign results, or findings which in the investigator's judgment are medically significant and that would impact the safety of the participant or the interpretation of the trial results.
  13. Participants with a history of prior exposure to centanafadine.
  14. Use of smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy, or other smoking cessation treatments (e.g., bupropion as Zyban, or varenicline) within 14 days of screening.
  15. Participants who participated in a clinical trial and were exposed to interventional trial medication within the last 30 days prior to screening or who participated in more than 2 interventional clinical trials within the past year.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Centanafadine

    Participants will receive centanafadine sustained release (SR) tablets, orally at a TDD of 400 milligrams (mg), administered as 200 mg doses, BID, approximately 4 to 6 hours apart, for a total of 7 weeks.

    Drug: Centanafadine

Interventions

  • 400 mg total daily dose Centanafadine Sustained Release, oral tablets

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Continuous Smoking Abstinence Rate

    Participants were considered abstinent from combustible cigarettes if the participant self-reported tobacco abstinence (no cigarette smoking, not even a puff) assessed by responses to daily messages throughout Weeks 4-7. Any participants lost to follow-up after receiving the investigational product, or who have smoked during Weeks 4-7 were counted as non-abstinent. The binomial confidence interval was based on normal approximation. If the number of abstinent or the number of non-abstinent ≤ 5, exact method was used.

    Time frame: Weeks 4 to 7

  2. Percentage of Participants With Continuous Smoking Abstinence Rate Determined Based on Expired Air Carbon Monoxide (CO) Reading Assessed Using the Vitalograph Breath CO Monitor

    Participants were considered abstinent from combustible cigarettes if the participants had an exhaled CO level of less than 5 parts per million (ppm) measured using the Vitalograph Breath CO monitor. Participants with actual data that they were smoking (CO value ≥ 5 ppm or any smoking record in self-report) were counted as non-abstinent The binomial confidence interval was based on normal approximation. If the number of abstinent or the number of non-abstinent ≤ 5, exact method was used.

    Time frame: Weeks 4 to 7

Secondary outcomes

  1. Percentage of Participants With Nausea

    Nausea was only considered when it was a treatment-emergent adverse event (TEAE). A TEAE is defined as an adverse event (AE) which starts after start of first IMP or an AE continues from baseline of the specific corresponding duration and was serious, trial drug-related or results in death, discontinuation, interruption or reduction of IMP.

    Time frame: From first dose of study drug to 7 days after receiving last dose (Up to Week 8)

07

Results

Posted Jun 13, 2025

Participant flow

Participants took part in the study at 2 investigative centers in the United States from 15 September 2021 to 31 May 2022.

Participant flow — Overall Study
MilestoneCentanafadine
Started50
Full analysis set50
Safety analysis set50
Completed36
Not completed14
Withdrew: Adverse event1
Withdrew: Non-compliance with study drug5
Withdrew: Withdrawal by subject6
Withdrew: Physician decision2

Outcome measures

PrimaryPercentage of Participants With a Continuous Smoking Abstinence Rate

Participants were considered abstinent from combustible cigarettes if the participant self-reported tobacco abstinence (no cigarette smoking, not even a puff) assessed by responses to daily messages throughout Weeks 4-7. Any participants lost to follow-up after receiving the investigational product, or who have smoked during Weeks 4-7 were counted as non-abstinent. The binomial confidence interval was based on normal approximation. If the number of abstinent or the number of non-abstinent ≤ 5, exact method was used.

Time frame:
Weeks 4 to 7
Reported as:
Number · percentage of participants
Percentage of Participants With a Continuous Smoking Abstinence Rate
percentage of participantsCentanafadine
Percentage of Participants With a Continuous Smoking Abstinence Rate0 (0.0 to 5.9)
PrimaryPercentage of Participants With Continuous Smoking Abstinence Rate Determined Based on Expired Air Carbon Monoxide (CO) Reading Assessed Using the Vitalograph Breath CO Monitor

Participants were considered abstinent from combustible cigarettes if the participants had an exhaled CO level of less than 5 parts per million (ppm) measured using the Vitalograph Breath CO monitor. Participants with actual data that they were smoking (CO value ≥ 5 ppm or any smoking record in self-report) were counted as non-abstinent The binomial confidence interval was based on normal approximation. If the number of abstinent or the number of non-abstinent ≤ 5, exact method was used.

Time frame:
Weeks 4 to 7
Reported as:
Number · percentage of participants
Percentage of Participants With Continuous Smoking Abstinence Rate Determined Based on Expired Air Carbon Monoxide (CO) Reading Assessed Using the Vitalograph Breath CO Monitor
percentage of participantsCentanafadine
Percentage of Participants With Continuous Smoking Abstinence Rate Determined Based on Expired Air Carbon Monoxide (CO) Reading Assessed Using the Vitalograph Breath CO Monitor2.0 (0.1 to 9.2)
SecondaryPercentage of Participants With Nausea

Nausea was only considered when it was a treatment-emergent adverse event (TEAE). A TEAE is defined as an adverse event (AE) which starts after start of first IMP or an AE continues from baseline of the specific corresponding duration and was serious, trial drug-related or results in death, discontinuation, interruption or reduction of IMP.

Time frame:
From first dose of study drug to 7 days after receiving last dose (Up to Week 8)
Reported as:
Number · percentage of participants
Percentage of Participants With Nausea
percentage of participantsCentanafadine
Percentage of Participants With Nausea12.0

Adverse events

Collected over From first dose of study drug to 7 days after receiving last dose (Up to Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Centanafadine0/50 (0%)1/50 (2%)35/50 (70%)
Most frequent serious events
Most frequent serious events
EventCentanafadine
AngioedemaSkin and subcutaneous tissue disorders1/50
Most frequent other events
Showing 10 of 13
Most frequent other events
EventCentanafadine
InsomniaPsychiatric disorders11/50
Decreased AppetiteMetabolism and nutrition disorders9/50
HeadacheNervous system disorders7/50
Drug EruptionSkin and subcutaneous tissue disorders7/50
NauseaGastrointestinal disorders6/50
DyspepsiaGastrointestinal disorders5/50
FatigueGeneral disorders5/50
DiarrhoeaGastrointestinal disorders4/50
GastritisGastrointestinal disorders4/50
Abdominal PainGastrointestinal disorders3/50

Baseline characteristics

Enrolled Analysis Set included all participants who signed an informed consent form (ICF) for the trial and were assigned to treatment at the baseline visit.

Age, Continuous
Age, Continuous(years)Centanafadine
Mean45.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Centanafadine
Female24
Male26
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Centanafadine
Hispanic or Latino2
Not Hispanic or Latino48
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Centanafadine
White31
Black or African American12
Asian4
Other1
Multiple2
08

Study locations

2 sites
  • Rose Research Center
    Charlotte, North Carolina 28262, United States
  • Rose Research Center
    Raleigh, North Carolina 27617, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2022, 8 months.

Results were first posted in Jun 2025, 3 years after primary completion. A results delay was requested in May 2023.

Of 51 phase 2 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Oct 4, 2021
StartActual
Sep 15, 2021
Primary completionActual
May 31, 2022
CompletionActual
May 31, 2022
Results delay requested
May 30, 2023
Results first posted
Jun 13, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05066724
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Sep 15, 2021
Primary completion
May 31, 2022
Completion
May 31, 2022
Results posted
Jun 13, 2025
Last update
Jun 13, 2025

Study contacts

Jed E Rose, Ph.D.
principal investigator · Rose Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion